Pharmacokinetics of prednisolone during administration of sirolimus in patients with renal transplants

Journal of Clinical Pharmacology

Volumn 36, Issue 12, 1996, Pages 1100-1106

  Jusko, William J ^a   Ferron, Geraldine M ^a   Mis, Suzette M ^a   Kahan, Barry D ^b   Zimmerman, James J ^c  

^a UNIVERSITY AT BUFFALO   (United States)

^b UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^c WYETH AYERST RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN; HYDROCORTISONE; PREDNISOLONE; PREDNISONE; RAPAMYCIN;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CORTICOSTEROID THERAPY; DRUG BLOOD LEVEL; DRUG ELIMINATION; FEMALE; GRAFT REJECTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; MALE; ORAL DRUG ADMINISTRATION; POSTOPERATIVE COMPLICATION;

EID: 0030477754     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1002/j.1552-4604.1996.tb04162.x     Document Type: Article

References (27)

1. Vezina C, Kudelski A, Sehgal S: Rapamycin (AY-22,989), a new antifungal antibiotic. I. Taxonomy of the producing streptomicete and isolation of the active principle. J Antibiot (Tokyo) 1975; 28:721-726.
2. Morris RE: Rapamycins: antifungal, antitumor, antiproliferative, and immunosuppressive macrolides. Transplant Rev 1992; 6:39-87.
3. Metclafe SM, Richards FM: Cyclosporine, FK506, and rapamycin: some effects on early activation events in serum-free, mitogen-stimulated mouse spleen cells. Transplantation 1990; 49:798-803.
4. Whiting PH, Woo J, Adam BJ, Hasan NU, Thomson AW: The effect of rapamycin on renal function in the rat: a comparative study with cyclosporine. Toxicol Lett 1991; 58:169-179.
5. Bansbach CC, Wancio D, Caccese RG, Shen CF, Sehgal SN: Rapamycin's inhibition of thymocyte proliferation, unlike that of cyclosporin A or prednisolone, is not associated with cytotoxicity. Ann N Y Acad Sci 1993; 685:114-116.
6. Boumpas DT, Paliogianni F, Anastassiou ED, Balow JE: Glucocorticosteroid action on the immune system: molecular and cellular aspects. Clin Exp Rheumatol 1991; 9:413-423.
7. Michnick SW, Rosen MK, Wandless TJ, Karplus M, Schreiber SL: Solution structure of FKBR, a rotamase enzyme and receptor for FK506 and rapamycin. Science 1991; 252:836-842.
8. Kay JE, Kromwel L, Doe SEA, Denyer M: Inhibition of T and B lymphocyte proliferation by rapamycin. Immunology 1991; 72:544-549.
9. Kahan BD, Gibbons S, Tejpal N, Chou TC, Stepkowski S: Synergistic effect of the rapamycin-cyclosporine combination: median effect analysis of in vitro immune performances by human T lymphocytes in PHA, CD3, and MLR proliferative and cytotoxicity assays. Transplant Proc 1991; 23:1090-1091.
10. Kahan BD, Gibbons S, Tejpal N, Stepkowski SM, Chou T-C: Synergistic interactions of cyclosporine and rapamycin to inhibit immune performances of normal human peripheral blood lymphocytes in vitro. Transplantation 1991; 51:232-239.
11. Yee GC: Recent advances in cyclosporine pharmacokinetics. Pharmacotherapy 1991;11(suppl):130S-134S.
12. Wald JA, Law RM, Ludwig EA, Sloan RR, Middleton E Jr, Jusko WJ: Evaluation of dose-related pharmacokinetics and pharmacodynamics of prednisolone in man. J Pharmacokinet Biopharm 1992; 20:567-589.
13. Frey FJ: Pharmacokinetic determinants of cyclosporine and prednisone in renal transplant patients. Kidney Int 1991; 39:1034-1050.
14. Honcharik N, Fryer J, Yatscoff R: Pharmacokinetics of rapamycin: single-dose studies in the rabbit. Ther Drug Monit 1992; 14:475-478.
15. Hricik DE, Almawi WY. Strom TB: Trends in the use of glucocorticoids in renal transplantation. Transplantation 1994; 57:979-989.
16. Grevel J: Optimization of immunosuppressive therapy using pharmacokinetic principles. Clin Pharmacokinet 1992; 23:380-390.
17. Rose JQ, Jusko WJ: Corticosteroid analysis in biological fluids by high-performance liquid chromatography. J Chromatogr B 1979; 162:273-280.
18. Jusko WJ, Pyszczynski NA, Bushway MS, D'Ambrosio R, Mis SM: Fifteen years of operation of a high-performance liquid Chromatographic assay for prednisolone, cortisol and prednisone in plasma. J Chromatogr B 1994; 658:47-54.
19. Yeh KC, Kwan KC: A comparison of numerical integrating algorithms by trapezoidal, Lagrange, and spline approximation. J Pharmacokinet Biopharm 1978; 6:69-98.
20. max for absorption rates in investigations of bioequivalence. Int J Clin Pharmacol Ther Toxicol 1991; 29:394-399.
21. Tornatore KM, Reed K, Walshe JJ, Venuto RC: Cortisol pharmacodynamic response to long-term methylprednisolone in renal transplant recipients. Pharmacotherapy 1994; 14:111-118.
22. Ferry JJ, Horvath AM, Bekersky I, Heath EC, Ryan CF, Coburn WA: Relative and absolute bioavailability of prednisone and prednisolone after separate oral and intravenous doses. J Clin Pharmacol 1988; 28:81-87.
23. Jusko WJ, Ludwig EA: Corticosteroids. In, Evans WE, Schentag JJ, Jusko WJ (eds.): Applied Pharmacokinetics: Principles of Therapeutic Drug Monitoring. Third Edition. Vancouver, WA: Applied Therapeutics, 1992;27-1-27-34.
24. Langhoff E, Flachs H, Ladefoged J, Huidberg EF: Intraindividual consistency of prednisolone kinetics during long-term prednisone treatment. Eur J Clin Pharmacol 1984;26:651-653.
25. Turgeon DK, Leichtman AB, Lown KS, Normolle DP, Debb GM, Merion RM, Watkins PB: P450 3A activity and cyclosporine dosing in kidney and heart transplant recipients. Clin Pharmacol Ther 1994; 56:253-260.
26. Sattler M, Guengerich P, Yun C-H, Christians U, Sewing K-F: Cytochrome P450 3A enzymes are responsible for biotransformation of FK506 and rapamycin in man and rat. Drug Metab Dispos 1992; 20:753-761.
27. Tornatore KM, Reed KA, Venuto RC: Racial differences in the pharmacokinetics of methylprednisolone in black and white renal transplant recipients. Pharmacotherapy 1993; 13:481-86.